Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Revenue projections:

Revenue projections for BIOCON
Revenue projections for BIOCON

BIOCON is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.

Financial Ratios:

currentRatio 1.15500
forwardPE 35.69782
debtToEquity 50.02400
earningsGrowth 0.00000
revenueGrowth 0.19600
grossMargins 0.59587
operatingMargins 0.09435
trailingEps 3.99000
forwardEps 10.25833

Biocon Limited's current ratio of 1.155 reflects its strong liquidity position. The company has enough cash reserves and current assets to service its short-term debt obligations, signaling that Biocon Limited is financially well-prepared to meet its liabilities without difficulty.
BIOCON's forward EPS surpasses its trailing EPS, indicating that the company is expected to be more profitable in the current financial year. This reflects growing confidence in BIOCON's earnings potential, suggesting stronger financial performance compared to the previous year.

Price projections:

Price projections for BIOCON
Price projections for BIOCON

The steady upward revision of Biocon Limited's price projections indicates growing confidence in the company's future. Analysts are increasingly optimistic about Biocon Limited's potential to deliver strong results and increased market value.

Recommendation changes over time:

Recommendations trend for BIOCON
Recommendations trend for BIOCON


Analysts have maintained a buy bias for BIOCON, which could prompt investors to consider the stock as a viable investment. With this positive outlook, BIOCON is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.